Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC

PharmaMar (MSE:PHM) announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.

The IDMC's recommendation came after an analysis of the safety data obtained with the first 80 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 compared with the standard treatment for this indication — topotecan or pegylated liposomal doxorubicin — in a total of 420 patients.

###

Media Contact

Paula Fern√°ndez
[email protected]
34-638-796-215
@PhrmMar

http://www.pharmamar.com

Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: